WitrynaImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non … WitrynaImmuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling …
Immuneering Announces Participation in September 2024 Investor ...
Witryna28 lut 2024 · The presentations will be webcast live and archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations. About Immuneering Corporation. Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to … Witryna27 lut 2024 · CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company … philips phone number netherlands
Immuneering Announces Participation in September Investor …
Witryna27 lut 2024 · After the live webcast, the event will be archived for 90 days in the Investor Relations section of Immuneering's website at Events & Presentations. About … Witryna20 maj 2024 · Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except … Witryna24 lut 2024 · Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy … philips photoframe manager download